Market Overview

Nature Communications Publishes Studies Comparing Triumvira's T Cell Antigen Coupler (TAC) Technology with CAR T Cell Therapy

Share:

Efficacy of Engineered T Cells can be Uncoupled from Toxicities
Observed with CAR T Cell Therapy

Triumvira
Immunologics, Inc.,
(Triumvira) a privately-held biopharmaceutical
company focused on designing safe and more effective T cell therapies
today announced the publication of a peer-reviewed article in today's
edition of Nature Communications, which describes the mechanism
of action of the company's T cell antigen coupler (TAC) technology,
designed to co-opt the natural biology of T cells to attack solid and
liquid tumors.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180803005063/en/

Benefits of Co-opting Natural T Cell Receptors (Graphic: Business Wire)

Benefits of Co-opting Natural T Cell Receptors (Graphic: Business Wire)

The article, titled "The chimeric TAC receptor co-opts the T
cell receptor yielding robust anti-tumor activity without toxicity
"
presents results from pre-clinical studies with human T cells engineered
with Triumvira's proprietary TAC
technology
directed against multiple antigens. The results clearly
demonstrate robust and antigen-specific cytokine production and
cytotoxicity in vitro and strong anti-tumor activity in a variety
of xenograft models, including solid and liquid tumors. In addition, the
study observes that HER2-TAC T cells demonstrate robust penetration and
local proliferation and activation in solid tumors.

"This peer-reviewed article provides scientific validation of our
platform TAC technology and provides future hope for patients by
potentially making T cell therapy more accessible to a much larger pool
of cancer patients," commented Paul Lammers, MD, MSc, President and
Chief Executive Officer. "Based on these data and other pre-clinical
data in hand, we continue with confidence to advance this program into
clinical development."

"Comparative studies in a solid tumor model demonstrated the unique
biological differences of the TAC and CAR receptors. Unlike the known
toxicities with CAR T cell therapy, this study indicated that TAC T
cells outperformed second generation CAR T cells, revealing both
increased tumor penetrating ability, anti-tumor efficacy and reduced
toxicity," commented Jonathan Bramson, PhD, Professor of Pathology and
Molecular Medicine, Vice Dean for Research at McMaster University,
Hamilton, ON, Canada, and Triumvira's co-founder and Acting Chief
Scientific Officer. "These results are exciting and help to elucidate
the mechanism of TAC T cells, which may have a superior therapeutic
index relative to CAR T cells."

About Triumvira Immunologics
Triumvira Immunologics, Inc. is
an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at
McMaster University and Bloom Burton & Co., a niche life-sciences
investment bank, with the vision of developing novel T cell therapies
that are safer and more efficacious than current cell therapy cancer
treatments, including chimeric antigen receptor (CAR) and engineered T
cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler
(TAC) technology recruits the entire natural T cell receptor and is
independent of the Major Histocompatibility Complex (MHC), allowing for
the development of better therapies for a broader range of patients with
either solid or liquid malignancies and with diseases other than cancer.
With operations spanning North America, our corporate offices are
located in Austin, Texas, and our research facilities are in Hamilton,
Ontario. For more information, visit www.triumvira.com
or send email inquiries to partners@triumvira.com.

View Comments and Join the Discussion!